Evidence map›Paper›PMID 42557684›Full record

ArticleMacromolecular bioscience2026

Recombinant Antifreeze Protein Type I as a Potential Peptide-Based Anti-Fouling Material for Biomedical Surfaces.

Kei Nishida, Yuma Horinouchi, Masayasu Mie, Eiry Kobatake

Abstract read
In one paragraph

Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kei NishidaDepartment of Life Science and Technology, School of Life Science and Technology, Institute of Science Tokyo, Yokohama, Japan.ORCID https://orcid.org/0000-0001-6493-5436
Yuma HorinouchiDepartment of Life Science and Technology, School of Life Science and Technology, Institute of Science Tokyo, Yokohama, Japan.
Masayasu MieDepartment of Life Science and Technology, School of Life Science and Technology, Institute of Science Tokyo, Yokohama, Japan.
Eiry KobatakeDepartment of Life Science and Technology, School of Life Science and Technology, Institute of Science Tokyo, Yokohama, Japan.

Funding

Japan Agency for Medical Research and Development 22ym0126813Japan Agency for Medical Research and Development 23ym0126813Japan Society for the Promotion of Science 21K18066Japan Society for the Promotion of Science 23H03738Japan Society for the Promotion of Science 23K17209Japan Society for the Promotion of Science 26K03291Koyanagi-FoundationTerumo Life Science FoundationYazaki Memorial Foundation for Science and Technology
6 · The paper itself

Abstract

Anti-fouling of material surfaces is a major concern in the performance of biomedical materials in biological environments. Surface modification of polymeric materials is an effective strategy for controlling the anti-fouling properties of biomedical materials. Synthetic polymers such as poly(ethylene glycol) (PEG), which exhibit high bioinertness and anti-fouling properties, are widely used. Peptide-based anti-fouling materials are gaining attention because of their biocompatibility, long-term biodegradability, and structural diversity. In this study, we explored the potential of antifreeze protein type I (AFP) from winter flounder as a peptide-based anti-fouling material. AFP possesses a simple α-helical structure of approximately 30 amino acid residues and presents an amphiphilic interface consisting of an ice-binding surface and a hydrophilic surface. We constructed a recombinant AFP that can be modified on a glass substrate and evaluated its anti-fouling properties. The AFP-modified substrates significantly suppressed the adsorption of plasma proteins, such as human albumin, fibrinogen, and fibronectin. Furthermore, adhesion of human ovarian cancer SKOV3 cells and mouse platelets to the substrates was suppressed by AFP modification. Notably, tandem-repeat AFP constructs exhibited high resistance to proteolytic enzymes, such as trypsin. These findings highlight the potential of recombinant AFP as a potential peptide-based anti-fouling material for biomedical applications.

Indexed as

Antifreeze Proteins, Type IBiocompatible MaterialsBiofoulingPeptidesRecombinant ProteinsAdsorptionAmino Acid SequenceAnimalsCell AdhesionCell Line, TumorFibrinogenFibronectinsFlounderHumansMicePlatelet AdhesivenessAntifreeze Proteins, Type IBiocompatible MaterialsFibrinogenFibronectinsPeptidesPolyethylene GlycolsRecombinant Proteinsanti‐foulingantifreeze proteinpeptideprotein adsorption

Identifiers

PMID42557684
PMCPMC13442990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.